Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
AIM AIM ImmunoTech Inc. daily Stock Chart
AIM [AMEX]
AIM ImmunoTech Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-2.55 Insider Own1.40% Shs Outstand17.49M Perf Week6.40%
Market Cap69.35M Forward P/E- EPS next Y-0.45 Insider Trans0.00% Shs Float26.07M Perf Month31.68%
Income-10.00M PEG- EPS next Q-0.10 Inst Own1.90% Short Float5.28% Perf Quarter15.15%
Sales0.20M P/S346.73 EPS this Y73.20% Inst Trans-4.25% Short Ratio0.18 Perf Half Y454.98%
Book/sh1.96 P/B1.36 EPS next Y9.80% ROA-40.30% Target Price- Perf Year-42.86%
Cash/sh1.08 P/C2.47 EPS next 5Y25.00% ROE-61.50% 52W Range0.38 - 7.50 Perf YTD388.97%
Dividend- P/FCF- EPS past 5Y44.30% ROI-63.20% 52W High-64.53% Beta-0.95
Dividend %- Quick Ratio42.30 Sales past 5Y-6.60% Gross Margin- 52W Low598.16% ATR0.27
Employees31 Current Ratio42.30 Sales Q/Q- Oper. Margin- RSI (14)54.58 Volatility11.19% 11.33%
OptionableNo Debt/Eq0.19 EPS Q/Q92.50% Profit Margin- Rel Volume0.58 Prev Close2.52
ShortableYes LT Debt/Eq0.18 Earnings- Payout- Avg Volume7.51M Price2.66
Recom2.00 SMA208.66% SMA5012.44% SMA20085.87% Volume4,373,471 Change5.56%
May-14-20 06:50AM  
AIM ImmunoTech Announces FDA Authorization for First Human Ampligen Trial in COVID-19 Patients with Cancer; Provides Corporate Business Update for the First Quarter of 2020
ACCESSWIRE +25.11%
Apr-29-20 06:30AM  
AIM ImmunoTechs CEO to Present at Maxims Infectious Disease Virtual Conference
ACCESSWIRE
Apr-20-20 06:30AM  
AIM ImmunoTechs CEO to Present at the Planet Microcap Showcase Virtual Investor Conference 2020
ACCESSWIRE
Apr-06-20 06:30PM  
AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic
ACCESSWIRE
01:00PM  
AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic
ACCESSWIRE
06:30AM  
AIM ImmunoTech Announces the National Cancer Institutes Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers
ACCESSWIRE
Mar-31-20 06:45AM  
AIM ImmunoTech Reports 2019 Year-end Financial Results
ACCESSWIRE
Mar-26-20 08:00AM  
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic
ACCESSWIRE +10.22%
Mar-09-20 06:30AM  
AIM ImmunoTechs Drug Ampligen to Be Tested by Japans National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19
ACCESSWIRE +190.48%
Mar-08-20 11:34AM  
Inovio shares rally after biotech says human trials of coronavirus vaccine will start in April
MarketWatch
Feb-27-20 06:30AM  
AIM ImmunoTech Joins with ChinaGoAbroad for an Ampligen China Entry Against COVID-19, the New SARS-like Coronavirus Disease Epidemic
ACCESSWIRE +42.50%
Feb-18-20 06:30AM  
AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic
ACCESSWIRE
Feb-12-20 06:30AM  
AIM ImmunoTechs CEO to Appear Live Today on FOX Business Networks The Claman Countdown and Cheddars Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus
ACCESSWIRE +17.92%
Feb-11-20 06:30AM  
AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen® for Use Against the SARS-like Wuhan 2019 Novel Coronavirus
GlobeNewswire +28.48%
06:30AM  
AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus
ACCESSWIRE
Feb-05-20 06:30AM  
AIM ImmunoTech Announces Completion of Third-Party Clinical Trial Using Ampligen in Combination with Other Therapies as Adjuvant Treatment of Peritoneal Surface Malignancies
ACCESSWIRE
Jan-16-20 05:27AM  
Read This Before Selling AIM ImmunoTech Inc. (NYSEMKT:AIM) Shares
Simply Wall St.
Dec-11-19 12:20PM  
AIM ImmunoTech to Present at the Investor Summit in Philadelphia
ACCESSWIRE
06:30AM  
AIM ImmunoTech to Present at the Investor Summit in Philadelphia
ACCESSWIRE
Dec-04-19 06:30AM  
AIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020
ACCESSWIRE -7.95%
Nov-15-19 10:25AM  
CORRECTION: AIM ImmunoTech Provides Business Update for the Third Quarter of 2019
ACCESSWIRE
06:30AM  
AIM ImmunoTech Provides Business Update for the Third Quarter of 2019
ACCESSWIRE
Oct-23-19 06:30AM  
AIM ImmunoTech to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
ACCESSWIRE
Oct-07-19 06:30AM  
AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified
ACCESSWIRE +7.23%
Sep-25-19 09:50AM  
AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering
ACCESSWIRE -43.37%
Sep-24-19 06:30AM  
AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center
ACCESSWIRE -14.53%
06:00AM  
AIM ImmunoTechs Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome
ACCESSWIRE
Sep-19-19 08:43AM  
AIM ImmunoTech Shares Spike Up 90% After $6.42M 'Breakthrough Award'
Benzinga +32.91%
06:50AM  
AIM ImmunoTech Inc. Announces the U.S. Department of Defenses Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer
ACCESSWIRE
Sep-16-19 06:50AM  
AIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer
ACCESSWIRE
Sep-13-19 06:50AM  
AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City
ACCESSWIRE
Sep-10-19 07:30AM  
AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center
ACCESSWIRE
Sep-09-19 07:45AM  
AIM ImmunoTech Inc. Announces its Name Change is Complete, Its New Website is Up and the Company Now Trades as Ticker Symbol 'AIM'
ACCESSWIRE
Sep-06-19 06:30AM  
AIM ImmunoTech to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 10th
ACCESSWIRE
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
open in yahoo | open in reuters | open in google